Cargando…
HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients
There are contrasting data in the literature about antituberculosis plasma drug concentrations in HIV-1-coinfected patients. We report the pharmacokinetics of rifampin, isoniazid, and pyrazinamide in a cohort of patients being treated for active tuberculosis, the majority of whom were coinfected wit...
Autores principales: | Rockwood, Neesha, Meintjes, Graeme, Chirehwa, Maxwell, Wiesner, Lubbe, McIlleron, Helen, Wilkinson, Robert J., Denti, Paolo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5038257/ https://www.ncbi.nlm.nih.gov/pubmed/27480859 http://dx.doi.org/10.1128/AAC.00480-16 |
Ejemplares similares
-
Relationship between Plasma and Intracellular Concentrations of Bedaquiline and Its M2 Metabolite in South African Patients with Rifampin-Resistant Tuberculosis
por: Ngwalero, Precious, et al.
Publicado: (2021) -
Pharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in Newly Diagnosed Pulmonary TB Patients in Tanzania
por: Denti, Paolo, et al.
Publicado: (2015) -
Early antituberculosis drug exposure in hospitalized patients with human immunodeficiency virus‐associated tuberculosis
por: Schutz, Charlotte, et al.
Publicado: (2020) -
The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis
por: Somoskovi, Akos, et al.
Publicado: (2001) -
Pharmacokinetics of antitubercular drugs in patients hospitalized with HIV-associated tuberculosis: a population modeling analysis
por: Abdelgawad, Noha, et al.
Publicado: (2022)